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Introduction: Bone is the most frequent site of breast cancer metastasis. Differences between those who present with de novo bone-only
metastasis (BOM) and those who progress to bone-only disease following a diagnosis of early-stage breast cancer are not clear. Such
differences in clinical course might have an impact on the aggressiveness of treatment. This study presents the clinical and pathological
features, along with treatment outcomes, of breast cancer patients with BOM in relation to the timing and type of bone metastasis.
Patients and Methods: Patients with breast cancer and BOM were retrospectively reviewed. De novo BOM was defined as bone
metastasis diagnosed at presentation or within the first 4 months of follow-up. Treatment outcomes of patients with de novo, compared
to those with subsequent BOM, are presented.
Results: 242 patients, median age (range) at diagnosis was 52 (27–80) years were enrolled. The majority of the patients (77.3%) had
de novo BOM with multiple sites of bone involvement (82.6%). At a median follow-up of 37.7 months, the median overall survival
(OS) for patients with de novo BOM disease was significantly shorter than those who developed so subsequently; 40.8 months (95%
CI, 51.1–184.1) compared to 80.9 months (95% CI, 36.4–47.9), p < 0.001. Tumor grade, hormone receptor status and type of bone
lesions (lytic versus sclerotic) had a significant impact on survival outcomes.
Conclusion: Breast cancer with de novo BOM is a distinct clinical entity with unfavorable prognosis and is associated with shorter
survival. Several risk factors for poor outcomes were identified and might inform treatment plans.
Keywords: breast cancer, bone metastasis, bone-only metastasis, de novo metastasis

Introduction
With an estimated 2.3 million new cases diagnosed in 2020, breast cancer continues to be the most commonly diagnosed
cancer worldwide.1,2 Over the past decade, breakthroughs in the treatment of breast cancer with the implementation of
novel and more effective therapeutic agents with better toxicity profile have improved the outlook of women diagnosed
with the disease.
Breast cancer is not a single disease, and its heterogeneity can be a challenge. Understanding the interplay between
the molecular and histopathological characteristics of the tumor, and their relationship with genetic and non-genetic risk
factors, has had profound implications on treatment advances, which correlate with improved outcomes.3 Despite these
advances, metastatic breast cancer remains a major leading cause of death. Though 5% or less of patients present with
advanced-stage disease at diagnosis, such percentage may reach 20–30% in developing countries,4,5 and another third of
patients with early-stage disease will develop distant metastasis during the course of their illness.6
Bone is a very common site of metastasis in patients with breast cancer, noted in 60%–80% of the patients and is the
first site of metastasis in 25%–40%.7,8 Bone metastasis from solid tumors, including breast cancer, may lead to several
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skeletal-related events that may include bone pain, hypercalcemia, vertebral and non-vertebral pathological fractures, in
addition to spinal cord compression that may mandate surgical intervention or radiation therapy.9,10
Compared to breast cancer with visceral metastasis, patients with bone-only metastasis (BOM) have better overall
survival (OS).11,12 Bone pain commonly complicates bone metastasis, may limit patients’ mobility and impair their
quality of life (QOL) leading to an increased demand for pain medications, including non-steroidal anti-inflammatory
drugs (NSAIDs) and narcotics with their usual complications.13,14 Additionally, patients with BOM are more exposed to
radiation therapy and surgical interventions,15 like internal fixations of pathological fractures, hip replacement and
vertebroplasty.16–18 Bone-modifying agents, including bisphosphonates and denosumab, commonly utilized in patients
with metastatic breast cancer to the bone, are associated with various short- and long-term adverse events.19
A limited number of studies identified the prognostic factors that may predict survival of breast cancer patients with
BOM and their impact on treatment strategies and outcomes. In this study, we describe the clinical and tumor
characteristics of patients with BOM whether diagnosed at presentation (de novo BOM) or subsequently following
treatment for early-stage disease (subsequent BOM) and explore factors that may predict treatment outcomes.

Methods
Patient Selection
Retrospectively, we reviewed all consecutive adult breast cancer patients diagnosed and treated at our institution between
July 2006 and December 2018. All patients with BOM breast cancer were included and classified according to the time
of diagnosis with bone metastasis. Patients were labeled as having de novo BOM disease if they had bone metastasis at or
within 4 months, of their initial diagnosis of breast cancer. Patients who progressed with BOM following the curative
management of their primary breast tumor or after a minimum of 4 months of treatment with neoadjuvant and/or
adjuvant systemic therapy are labelled as “subsequent BOM”.20 Bone metastasis was diagnosed on the basis of imaging
studies using bone scan, computed tomography (CT) scan, positron emission tomography (PET) scan, or magnetic
resonance imaging (MRI).
Furthermore, clinical characteristics including age at diagnosis, tumor grade, subtype, hormone receptor (HR), human
epidermal growth factor receptor-2 (HER2) status, sites of BOM, number of sites of bone metastasis; single versus
multiple, were analyzed. Treatment modalities including endocrine therapy and chemotherapy were obtained from
medical records. The need for bone-modifying agents like bisphosphonates, radiotherapy, and/or vertebroplasty was
also described.
Estrogen (ER) and progesterone (PR) receptors were defined as per the College of American Pathologists (CAP) and the
American Society of Clinical Oncology (ASCO). Both were considered positive if staining of tumor cell nuclei was 1% or
more. HER2 was tested using immune histochemical staining (IHC) and scored zero to +3; tumors were considered
negative if IHC scores were zero or +1 and positive if +3. Fluorescence in situ hybridization (FISH) was performed for
tumors with +2 scores (considered equivocal).
The study was conducted in accordance with the international and local regulations and guidelines on human research
including the 1964 Helsinki declaration and its later amendments. The study (protocol number:19-KHCC-72) was
approved by the Institutional Review Board (IRB) at King Hussein Cancer Center. Given the retrospective nature of
data collection and lack of patients’ identifier, informed consent was waived by the IRB.

Statistical Analysis
A descriptive analysis of patients’ information was done. Categorical data, such as age group, grade, and other factors,
were presented as counts and percentages. In general, continuous variables were analyzed using t-test or a non-parametric
test depending on the assumptions required for each test. The Kaplan–Meier method was used to estimate OS curves and
progression-free survival. A Log rank test was used to compare patients’ survival times between different factor groups.
The OS time was calculated from the date of breast cancer diagnosis to death from any cause; patients who were alive at
the last follow-up were censored at that time. The progression-free survival (PFS) time was calculated from the date of
diagnosis till the first evidence of disease progression in bone, metastasis to any other site or death due to any cause.

2520

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/CMAR.S369910

DovePress

Cancer Management and Research 2022:14

Dovepress

Marie et al

Survival was expressed as a median with 5-year survival rate. A significance criterion of p <0.05 was used in the
analysis. Analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).

Results
Patients Characteristics
A total of 242 patients, 2 males, were included in the final analysis. The median age (range) at the time of breast cancer
diagnosis was 52 (27–80) years. The majority (n = 187, 77.3%) of identified patients presented with de novo bone-only
metastatic breast cancer (mBC), while 55 (22.7%) patients were initially diagnosed with early-stage disease, then
progressed with bone-only metastasis. Table 1 summarizes patients’ characteristics.

Tumor Characteristics
Invasive ductal carcinoma (IDC) was the most common pathology (n = 193, 79.8%). High-grade (grade III) tumors were
identified in 66 (27.3%) patients and 44 (18.2%) had HER2-positive disease. Majority (n = 220, 90.9%) of patients had
hormone receptor (HR)-positive disease, while 13 (5.4%) were triple-negative (hormone-receptor negative and HER2negative), Table 1.

Bone Involvement
Solitary bone metastasis was reported in 42 (17.4%) patients, while 200 (82.6%) patients had multiple sites of bone
involvement. Vertebral column metastases was reported in 130 (53.7%) patients. Bone metastasis was lytic in 90 (37.2%)
patients, 49 (20.2%) had sclerotic disease and 20 (8.3%) patients had mixed (lytic and sclerotic) bone metastasis, Table 2.
Table 1 Clinical Characteristics (n = 242)
Characteristic

Number (%)

Gender
Female

240 (99.2)

Male

2 (0.8%)

Age group (years)
< 40
40–49

43 (17.7)
64 (26.4)

50–59

60 (24.7)

60–69
≥ 70

47 (19.4)
28 (11.5)

Pathology
IDC

193 (79.8)

ILC

33 (13.6)

Others
NA

11 (4.5)
5 (2.1)

Grade
I

11 (4.5)

II

140 (57.9)

III
NA

66 (27.3)
25 (10.3)

Lymphovascular invasion
(LVI)
Positive

49 (20.2)

Negative
NA

61 (25.2)
132 (54.5)

(Continued)
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Table 1 (Continued).
Characteristic

Number (%)

Hormone receptors status
Positive

220 (90.9)

Negative
NA

21 (8.7)
1 (0.4)

Estrogen receptor (ER)
Positive

217 (89.7)

Negative

23 (9.5)

NA

2 (0.8)

Progesterone receptor
(PR)
Positive

203 (83.9)

Negative

37 (15.3)

NA

2 (0.8)

HER2-neu status
Positive
Negative

44 (18.2)
187 (77.3)

NA

11 (4.5)

Triple-negative disease
Yes

13 (5.4)

No
NA

218 (90.1)
11 (4.5)

Abbreviations: NA, not available; HER2, human epidermal
growth factor receptor-2; IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma.

Table 2 Features of Bone Metastasis
Characteristic

Number (%)

Time to diagnosis
De novo (< 4 months of diagnosis)

187 (77.3%)

Subsequent (≥ 4 months of diagnosis)

55 (22.7%)

Number of bone metastatic sites
Single
Multiple

42 (17.4%)
200 (82.6%)

Type of bone metastases
Lytic

90 (37.2%)

Sclerotic

49 (20.2%)

Mixed
Unknown

20 (8.3%)
83 (34.3%)

Spine involvement
Yes

29 (12.0%)

No

213 (88.0%)

Treatment
Endocrine therapy (ET) was utilized in the first-line setting in 211 (87.2%) patients. Among those, 128 (60.7%) received
aromatase inhibitors (AI), while 83 (39.3%) patients received tamoxifen, with or without gonadotropin-releasing
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hormone (GnRH) agonists. Only 57 (23.6%) patients received chemotherapy through their course of management, mostly
because of disease progression or negative hormone-receptor status. Bisphosphonate, mainly intravenous zoledronic acid,
was utilized in 209 (86.4%) of patients. Palliative radiation therapy to at least one site of bone metastasis was given to
101 (41.0%), and 29 (12.0%) underwent vertebroplasty.

Treatment Outcomes
At a median follow-up of 37.7 months, the 5-year OS for the whole group was 41.8%. Survival of patients with subsequent
BOM was significantly better than those with de novo BOM (60.5% vs 35.5%, respectively, log-rank p < 0.0001), Figure 1A.
Similarly, the 5-year PFS for the whole group was 22.8% (13.4% for de novo and 49.0% for the subsequent BOM group), with

Figure 1 Overall survival (A) and progression-free survival (B) for both groups; de novo bone-only metastasis (BOM) and subsequent metastasis.
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a median time to progression of 19.4 (95% CI, 16.07–20.62) months for those diagnosed with de novo BOM at presentation
and 50.7 (95% CI, 32.98–126.7) months for patients with subsequent BOM (Log-rank p = 0.0001), Figure 1B. At time of last
follow-up, 12 (4.9%) of 242 patients had died and majority (n = 185, 76.4%) had disease progression in the bone (n = 48,
19.8%) or visceral organs (n = 137, 56.6%), while another 45 (18.6%) continued to have a stable disease.
Table 3 summarizes the prognostic factors that affected survival for BOM. Histologic grade impacted survival
significantly; women with poorly differentiated tumors (grade-III) had 5-year OS of 26.6%, compared to 64.9% and
43.6% for grades I and II, respectively (log-rank p = 0.01), Figure 2. Additionally, 5-year PFS was 9.6% for patients with
grade-III disease, compared to 27.3% and 23.4% for those with grade-I and II, respectively (log-rank p = 0.005),
Figure 2B.
The nature of bone metastasis also affected treatment outcomes, with a 5-year overall survival of 46.0%, 54.9%, and
43.0% for patients with lytic, sclerotic, or mixed bone metastasis, respectively (log-rank p = 0.01), Figure 3A. However,
no difference was observed in PFS (log-rank p = 0.934), Figure 3B. We also studied the impact of tumor subtype, based
on hormonal receptor (HR) and HER2 status, on treatment outcomes. Longer overall survival was observed in patients
with HR-positive/HER2-negative subtype (5-year OS of 45.9%) compared to 34.2% for those with HR-positive/HER2positive subtype and 11.5% for those with triple-negative disease (log-rank p = 0.052), Figure 4A. However, no
significant differences were observed in PFS among the different groups, Figure 4B. In multivariate analysis, de
Table 3 Prognostic Factors Affecting Survival of Patients with BOM
Characteristic

5-Year Progression-Free Survival

5-Year Overall Survival

Percentage (%)

Percentage (%)

p-value

Age (year)
< 50

22.7

0.55
44.9

≥ 50

22.7

39.2

Tumor grade
I

27.3

64.9

II
III

23.4
9.6

43.6
26.6

HER2 status
Negative

23.1

43.6

Positive

15.6

32.9

Estrogen receptor (ER)
Negative

16.3

13.7

Positive

23.1

44.5

Progesterone receptor (PR)
Negative

17.7

20.6

Positive

23.3

45.5

Number of bone lesions
Multiple

20.6

39.1

Single

34.5

54.8

Type of bone metastasis
Lytic

28.2

46.0

Sclerotic
Mixed

21.5
14.6

54.9
43.0

0.21

0.005

0.01

0.03

0.79

0.15

0.005

0.09

0.004

0.08

0.08

0.93

Time of bone metastasis

p-value

0.01

< 0.0001

< 0.0001

De novo

13.4

35.5

Subsequent

49

60.5

Abbreviations: BOM, bone-only metastases; HER2, human epidermal growth factor receptor-2.

2524

Powered by TCPDF (www.tcpdf.org)

https://doi.org/10.2147/CMAR.S369910

DovePress

Cancer Management and Research 2022:14

Dovepress

Marie et al

Figure 2 Overall survival (A) and progression-free survival (B) according to tumor grade.

novo bone metastasis versus subsequent metastasis (hazard ratio = 2.81, 95% CI, 1.65–4.79, p = 0.0001), and to a lesser
extent lytic versus sclerotic bone lesions (hazard ratio = 1.18, 95% CI, 0.46–1.55) were associated with poor overall
survival, while de novo bone metastasis, HER2 positivity and high tumor grade were all associated with poor PFS
(Table 4).
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Figure 3 Survival according to type of bone metastasis: (A) overall survival, (B) progression-free survival.

Discussion
Bone is the most common site of metastasis in breast cancer; some postmortem studies had shown that up to 75% of
patients may have bone metastasis during the course of their disease.21–23 Several studies had used preclinical models for
a better understanding of tumor biology and to explain its natural course.24–26 Bone metastasis, alone or when associated
with visceral involvement, may result in significant bone pain and may impair patients’ quality of life. Bone-only
metastasis is usually treated less aggressively, especially so in patients with HR-positive and HER2-negative subtypes.
Endocrine treatment including tamoxifen, aromatase inhibitors (AI) or fulvestrant, mostly with cyclin-dependent kinase
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Figure 4 Survival according to hormonal receptor (HR) and HER2 status: (A) overall survival, (B) progression-free survival.

4/6 (CDK4/6) inhibitors, are the first choice to treat patients with HR-positive and HER2-negative disease.27,28 Options
for subsequent therapies include another endocrine therapy (with or without CDK4/6 inhibitors, if not used in the firstline setting), or exemestane with everolimus.29,30 Patients with PIK3CA (phosphoinositide 3-kinase) mutation can be
offered alpelisib, a PIK3CA-inhibitor, along with fulvestrant (if not previously used).31,32 Chemotherapeutic agents are
options for HR-negative or resistant tumors, as well as for patients in whom a rapid response is desired.33 Patients with
HER2-positive BOM disease are less-commonly encountered. Agents targeting and blocking HER2 receptor are
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Table 4 Multivariate Analysis and Impact of Prognostic Factors on PFS
Parameter

p-value

Hazard Ratio

95% Confidence Interval

Time to bone metastasis

De novo versus subsequent

<0.0001

2.989

1.892–4.720

HER2

Positive versus Negative

0.0076

1.693

1.150–2.492

Grade

II versus I

0.0189

1.093

0.546–2.191

1.751

0.851–3.601

III versus I

important in the first- and subsequent-line settings, mostly used in combination with chemotherapy or endocrine therapy
(in hormone receptor-positive disease).34–38
Bone-only metastasis is a unique entity that describes patients who present with bone involvement but with no other
organ metastasis. BOM is not extensively evaluated by large prospective trials as a distinct entity due to the fact that bone
metastasis, until the most recent modification, is considered a non-measurable disease, based on RECIST criteria.39
Compared to other breast cancer patients with visceral metastasis, patients with BOM usually have better
prognosis.40–43 A recent French study identified a total of 20,095 women with metastatic breast cancer; 22.4% (n =
5041) of them had BOM. Regardless of the HR or HER2 status, patients with BOM had a better adjusted OS compared
with non-BOM metastatic breast cancer; 52.1 months (95% CI, 50.3–54.1) versus 34.7 months (95% CI, 34.0–35.6),
respectively. Progression-free survival (PFS) was also better; 13.1 months (95% CI, 12.6–13.8) versus 8.5 months (95%
CI, 8.3–8.7), respectively.44
Multiple studies have shown that the survival of patients with de novo metastatic breast cancer is significantly better
compared to that of patients who relapse following treatment for early-stage disease.45–48 Very few, however, had addressed
such difference in those with BOM. Our study clearly illustrates that patients who present with de novo metastatic BOM have
significantly worse outcome compared to those who develop so following a presentation with early-stage disease (5-year OS
36% versus 61%, p < 0.0001). Similar trends were also observed for PFS (14% versus 49%, p < 0.0001). Such data may carry
a significant impact on the aggressiveness of anti-cancer therapy and may help physicians address patients with their
anticipated disease course. Similar conclusions were reached by a study from MD Anderson Cancer Center (MDACC) in
which a total of 1048 evaluable patients with BOM were identified, the majority of them were HR-positive/HER2-negative
(78%). Median OS from the time of breast cancer diagnosis was 8.7 years (95% CI, 8.0–9.7) and varied significantly by tumor
subtype. Survival was significantly shorter (p < 0.0001) for the 442 patients with de novo BOM disease (defined similar to the
one used in our study).49 However, a smaller study from Korea reached different conclusions. In this study, medical records of
110 breast cancer patients were retrospectively reviewed to identify patients with BOM. Contrary to our study cohort, only
a minority of the patients presented with de novo BOM (n = 19, 17.3%), while the majority (n = 91, 82.7%) had BOM
following a diagnosis and treatment of early-stage disease (subsequent BOM group). At a median follow-up of 55 months, the
estimated 10-year OS was 35% for the whole group. Similarly, contrary to our findings, the 5-year OS for patients with de
novo BOM was better than that for patients with subsequent bone metastasis (60.2% vs 44.1%); nonetheless, the difference
was not statistically significant (p = 0.136).42
Generally, regardless of the metastatic sites, positive hormonal receptor status in metastatic breast cancer confers a better
survival compared to those with HR-negative, HER2-positive or those with triple-negative disease.50–52 This also holds true for
those with BOM as illustrated in our study (Figure 4) and in another MDACC study, as well.11 In the Korean study discussed
above, a multivariate analysis showed that solitary bone metastasis (hazard ratio = 0.32; 95% CI, 0.14–0.72), therapy with
bisphosphonate [hazard ratio = 0.18; 95% CI, 0.07–0.43], and ER-positivity (hazard ratio = 0.51; 95% CI, 0.28–0.94), were
significantly associated with improved overall survival.42
Our findings, in addition to previously published studies, can be used to develop a scoring system, based on clinical
and pathological features, that may potentially help physicians tailor treatment plans based on the aggressiveness of the
disease, as judged by such scoring system.
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Our study is not without limitations. The retrospective nature of the study and the relatively small population of patients
included from a single center may limit the generalization of our conclusions. However, we believe our study presents a realworld data for a cohort of patients treated on a unified clinical practice guidelines at a tertiary care cancer center.

Conclusions
Bone-only metastatic breast cancer is a distinct clinical entity and is usually associated with favorable prognosis. On the
other hand, de novo BOM compared to subsequent metastasis following a diagnosis of early-stage disease, is less
favorable and is usually associated with shorter survival. Triple-negative, HER2-positive, high-grade tumors and lytic or
multiple bone lesions may reflect negatively on treatment outcome of bone-only metastatic breast cancer.
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